Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Historical Holders from Q1 2018 to Q3 2025

Symbol: CUE on Nasdaq
Type / Class: Equity / Common Stock, $0.001 par value per share
Shares outstanding: 43,411,663
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 18,058,960
Holdings value: $12,982,249
% of all portfolios: 0%
Number of holders: 52
Number of buys: 14
Number of sells: -16
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Filer	Ownership	Change %	Holdings Value	Nb Shares	Change %	Reporting Name	Report Period
Bleichroeder LP	9.99%	0%	$5,269,789	6,127,662	0%	Bleichroeder LP	19 Mar 2025
STROME MARK E	4.99%		$1,862,968	2,166,242		Mark E. Strome	14 Nov 2022
Slate Path Capital LP	1.4%		$790,199	918,836		Slate Path Capital LP	31 Dec 2024

Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	18,058,960	$12,982,249	+$519,709			$0.7187	52
2025 Q2	17,351,508	$11,856,298	+$3,983,649	$0	$0	$0.6823	46
2025 Q1	11,402,706	$10,374,424	-$452,161	$1,275	$9,201	$0.911	49
2024 Q4	11,759,494	$12,816,995	-$1,528,241	$1,308	$23,980	$1.09	55
2024 Q3	13,910,388	$10,533,734	-$288,922	$1,969	$10,904	$0.7572	50
2024 Q2	13,807,875	$17,121,019	-$3,730,383	$13,764	$69,564	$1.24	72
2024 Q1	16,387,055	$30,971,606	+$2,715,659	$73,899	$24,381	$1.89	74
2023 Q4	14,886,167	$39,304,464	+$2,537,424	$71,544	$287,496	$2.64	80
2023 Q3	14,014,675	$32,148,839	-$634,604	$71,300	$59,110	$2.3	75
2023 Q2	13,849,849	$50,545,862	+$6,687,288	$23,725	$48,910	$3.65	77
2023 Q1	12,055,434	$43,037,472	-$2,540,576	$8,925	$102,816	$3.57	62
2022 Q4	12,761,302	$36,370,518	+$155,907	$6,840	$101,175	$2.85	60
2022 Q3	12,797,287	$28,665,093	-$2,995,285	$0	$70,000	$2.23	61
2022 Q2	14,083,808	$35,042,763	-$10,988,434	$38,000	$97,000	$2.49	68
2022 Q1	17,812,661	$87,010,965	+$4,491,451	$444,000	$866,000	$4.88	97
2021 Q4	16,533,577	$187,228,947	-$11,058,319	$703,000	$1,468,000	$11.31	88
2021 Q3	16,892,813	$245,597,815	-$23,967,610	$662,000	$1,530,000	$14.57	87
2021 Q2	18,582,224	$216,368,968	-$2,774,327	$1,601,000	$631,000	$11.65	89
2021 Q1	18,817,560	$229,653,033	-$6,452,286	$3,001,000	$707,000	$12.2	88
2020 Q4	19,314,982	$241,658,115	-$3,019,434	$2,723,000	$357,000	$12.51	94
2020 Q3	19,517,235	$293,948,076	+$49,950,366	$453,000	$635,000	$15.05	90
2020 Q2	16,042,165	$393,156,090	+$84,955,728	$1,525,000	$1,145,000	$24.51	99
2020 Q1	13,033,369	$184,956,981	+$36,613,314	$329,000		$14.19	72
2019 Q4	10,554,208	$167,568,706	+$63,118,277			$15.88	60
2019 Q3	6,080,606	$51,262,809	+$13,288,944			$8.43	44
2019 Q2	4,501,012	$40,453,546	+$9,997,120			$8.99	36
2019 Q1	3,453,175	$26,693,413	+$1,831,681			$7.73	37
2018 Q4	3,229,210	$15,171,419	-$2,037,779			$4.7	34
2018 Q3	3,579,962	$32,396,140	+$3,237,621			$9.05	36
2018 Q2	3,148,586	$37,344,175	+$15,445,827			$11.86	37
2018 Q1	1,844,607	$25,915,405	+$25,915,405			$14.05	28